Romiplostim in chemotherapy-induced thrombocytopenia: A review of the literature.
chemotherapy
peptibody
platelet growth factors
romiplostim
thrombocytopenia
thrombopoietin receptor agonists
Journal
Cancer medicine
ISSN: 2045-7634
Titre abrégé: Cancer Med
Pays: United States
ID NLM: 101595310
Informations de publication
Date de publication:
Aug 2024
Aug 2024
Historique:
revised:
04
06
2024
received:
24
11
2023
accepted:
13
06
2024
medline:
13
8
2024
pubmed:
13
8
2024
entrez:
13
8
2024
Statut:
ppublish
Résumé
Chemotherapy-induced thrombocytopenia (CIT) is a common challenge of cancer therapy and can lead to chemotherapy dose reduction, delay, and/or discontinuation, affecting relative dose intensity, and possibly adversely impacting cancer care. Besides changing anticancer regimens, standard management of CIT has been limited to platelet transfusions and supportive care. Use of the thrombopoietin receptor agonist romiplostim, already approved for use in immune thrombocytopenia, has shown promising signs of efficacy in CIT. In a phase 2 prospective randomized study of solid tumor patients with platelet counts <100 × 10
Substances chimiques
romiplostim
GN5XU2DXKV
Receptors, Fc
0
Thrombopoietin
9014-42-0
Recombinant Fusion Proteins
0
Antineoplastic Agents
0
Receptors, Thrombopoietin
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e7429Informations de copyright
© 2024 The Author(s). Cancer Medicine published by John Wiley & Sons Ltd.
Références
Kuter DJ. Managing thrombocytopenia associated with cancer chemotherapy. Oncology (Williston Park). 2015;29(4):282‐294.
Luz JH, Luz PM, Marchiori E, et al. Partial splenic embolization to permit continuation of systemic chemotherapy. Cancer Med. 2016;5(10):2715‐2720. doi:10.1002/cam4.856
Bussel JB, Soff G, Balduzzi A, Cooper N, Lawrence T, Semple JW. A review of romiplostim mechanism of action and clinical applicability. Drug Des Devel Ther. 2021;15:2243‐2268. doi:10.2147/dddt.S299591
Kam T, Alexander M. Drug‐induced immune thrombocytopenia. J Pharm Pract. 2014;27(5):430‐439. doi:10.1177/0897190014546099
Dy GK, Adjei AA. Understanding, recognizing, and managing toxicities of targeted anticancer therapies. CA Cancer J Clin. 2013;63(4):249‐279. doi:10.3322/caac.21184
Epstein RS, Aapro MS, Basu Roy UK, et al. Patient burden and real‐world Management of Chemotherapy‐Induced Myelosuppression: Results from an online survey of patients with solid tumors. Adv Ther. 2020;37(8):3606‐3618. doi:10.1007/s12325-020-01419-6
Schiffer CA, Bohlke K, Delaney M, et al. Platelet transfusion for patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2018;36(3):283‐299. doi:10.1200/jco.2017.76.1734
Shaw JL, Nielson CM, Park JK, Marongiu A, Soff GA. The incidence of thrombocytopenia in adult patients receiving chemotherapy for solid tumors or hematologic malignancies. Eur J Haematol. 2021;106(5):662‐672. doi:10.1111/ejh.13595
Wu Y, Aravind S, Ranganathan G, Martin A, Nalysnyk L. Anemia and thrombocytopenia in patients undergoing chemotherapy for solid tumors: a descriptive study of a large outpatient oncology practice database, 2000‐2007. Clin Ther. 2009;31(Pt 2):2416‐2432. doi:10.1016/j.clinthera.2009.11.020
Kuter DJ. Biology and chemistry of thrombopoietic agents. Semin Hematol. 2010;47(3):243‐248. doi:10.1053/j.seminhematol.2010.02.005
Soff G, Leader A, Al‐Samkari H, et al. Management of chemotherapy‐induced thrombocytopenia: Guidance from the ISTH subcommittee on hemostasis and malignancy. J Thromb Haemost. 2024;22(1):53‐60. doi:10.1016/j.jtha.2023.09.031
Al‐Samkari H. Optimal management of chemotherapy‐induced thrombocytopenia with thrombopoietin receptor agonists. Blood Rev. 2024;63:101139. doi:10.1016/j.blre.2023.101139
Matulonis UA, Monk BJ. PARP inhibitor and chemotherapy combination trials for the treatment of advanced malignancies: Does a development pathway forward exist? Ann Oncol. 2017;28(3):443‐447. doi:10.1093/annonc/mdw697
Tochigi T, Kikushige Y, Miyamoto T, Akashi K. IMiDs cause thrombocytopenia by the inhibition of proplatelet formation, through blocking estradiol autocrine loop in human megakaryocytes. Blood. 2016;128(22):894. doi:10.1182/blood.V128.22.894.894
Ali A, Bluteau O, Messaoudi K, et al. Thrombocytopenia induced by the histone deacetylase inhibitor abexinostat involves p53‐dependent and ‐independent mechanisms. Cell Death Dis. 2013;4(7):e738. doi:10.1038/cddis.2013.260
Fried S, Avigdor A, Bielorai B, et al. Early and late hematologic toxicity following CD19 CAR‐T cells. Bone Marrow Transplant. 2019;54(10):1643‐1650. doi:10.1038/s41409-019-0487-3
Jotatsu T, Oda K, Yamaguchi Y, et al. Immune‐mediated thrombocytopenia and hypothyroidism in a lung cancer patient treated with nivolumab. Immunotherapy. 2018;10(2):85‐91. doi:10.2217/imt-2017-0100
Shi DS, Smith MC, Campbell RA, et al. Proteasome function is required for platelet production. J Clin Invest. 2014;124(9):3757‐3766. doi:10.1172/jci75247
Danese E, Montagnana M, Favaloro EJ, Lippi G. Drug‐induced thrombocytopenia: Mechanisms and laboratory diagnostics. Semin Thromb Hemost. 2020;46(3):264‐274. doi:10.1055/s-0039-1697930
Zeuner A, Signore M, Martinetti D, Bartucci M, Peschle C, De Maria R. Chemotherapy‐induced thrombocytopenia derives from the selective death of megakaryocyte progenitors and can be rescued by stem cell factor. Cancer Res. 2007;67(10):4767‐4773. doi:10.1158/0008-5472.Can-06-4303
De Silva E, Kim H. Drug‐induced thrombocytopenia: focus on platelet apoptosis. Chem Biol Interact. 2018;284:1‐11. doi:10.1016/j.cbi.2018.01.015
Jardim DL, Rodrigues CA, Novis YAS, Rocha VG, Hoff PM. Oxaliplatin‐related thrombocytopenia. Ann Oncol. 2012;23(8):1937‐1942. doi:10.1093/annonc/mds074
Quirk SK, Shure AK, Agrawal DK. Immune‐mediated adverse events of anticytotoxic T lymphocyte‐associated antigen 4 antibody therapy in metastatic melanoma. Transl Res. 2015;166(5):412‐424. doi:10.1016/j.trsl.2015.06.005
Lonial S, Waller EK, Richardson PG, et al. Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma. Blood. 2005;106(12):3777‐3784. doi:10.1182/blood-2005-03-1173
Chang XF, Ren XL, Yang JQ, et al. Evaluation of efficacy and safety of PARP inhibitors in breast cancer: A systematic review and meta‐analysis. Breast. 2021;59:44‐50. doi:10.1016/j.breast.2021.05.009
Bulbul A, Mustafa A, Chouial S, Rashad S. Idiopathic thrombocytopenic purpura and autoimmune neutropenia induced by prolonged use of nivolumab in Hodgkin's lymphoma. Ann Oncol. 2017;28(7):1675‐1676. doi:10.1093/annonc/mdx159
Iyama S, Takada K, Yoshida M, Takahashi D, Kobune M. Acquired amegakaryocytic thrombocytopenic purpura possibly induced by anti‐PD‐1 antibody. Ann Hematol. 2020;99(7):1669‐1670. doi:10.1007/s00277-020-04053-y
Hata S, Abe S. Severe immune thrombocytopenia induced by nivolumab in a patient with metastatic renal cell carcinoma. Urol Case Rep. 2020;32:101128. doi:10.1016/j.eucr.2020.101128
Sui JD, Wang Y, Wan Y, Wu YZ. Risk of hematologic toxicities with programmed cell death‐1 inhibitors in cancer patients: A meta‐analysis of current studies. Drug Des Devel Ther. 2018;12:1645‐1657. doi:10.2147/dddt.S167077
Al‐Samkari H, Parnes AD, Goodarzi K, Weitzman JI, Connors JM, Kuter DJ. A multicenter study of romiplostim for chemotherapy‐induced thrombocytopenia in solid tumors and hematologic malignancies. Haematologica. 2021;106(4):1148‐1157. doi:10.3324/haematol.2020.251900
Liu X, Liang X, Liang J, Li Y, Wang J. Immune thrombocytopenia induced by immune checkpoint inhibitors in solid cancer: Case report and literature review. Front Oncol. 2020;10:530478. doi:10.3389/fonc.2020.530478
Soff GA, Miao Y, Bendheim G, et al. Romiplostim treatment of chemotherapy‐induced thrombocytopenia. J Clin Oncol. 2019;37(31):2892‐2898. doi:10.1200/jco.18.01931
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Hematopoietic Growth Factors. 2024 https://www.nccn.org/professionals/physician_gls/pdf/growthfactors.pdf
Izak M, Bussel JB. Management of thrombocytopenia. F1000Prime Rep. 2014;6:45. doi:10.12703/p6-45
Common Terminology Criteria for Adverse Events (CTCAE). Last Updated: 04/19/21. https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_60
Elting LS, Rubenstein EB, Martin CG, et al. Incidence, cost, and outcomes of bleeding and chemotherapy dose modification among solid tumor patients with chemotherapy‐induced thrombocytopenia. J Clin Oncol. 2001;19(4):1137‐1146. doi:10.1200/jco.2001.19.4.1137
Al‐Samkari H, Soff GA. Clinical challenges and promising therapies for chemotherapy‐induced thrombocytopenia. Expert Rev Hematol. 2021;14(5):437‐448. doi:10.1080/17474086.2021.1924053
Al‐Samkari H, Kolb‐Sielecki J, Safina SZ, Xue X, Jamieson BD. Avatrombopag for chemotherapy‐induced thrombocytopenia in patients with non‐haematological malignancies: An international, randomised, double‐blind, placebo‐controlled, phase 3 trial. Lancet Haematol. 2022;9(3):e179‐e189. doi:10.1016/s2352-3026(22)00001-1
Denduluri N, Lyman GH, Wang Y, et al. Chemotherapy dose intensity and overall survival among patients with advanced breast or ovarian cancer. Clin Breast Cancer. 2018;18(5):380‐386. doi:10.1016/j.clbc.2018.02.003
Crawford J, Denduluri N, Patt D, et al. Relative dose intensity of first‐line chemotherapy and overall survival in patients with advanced non‐small‐cell lung cancer. Support Care Cancer. 2020;28(2):925‐932. doi:10.1007/s00520-019-04875-1
Loibl S, Skacel T, Nekljudova V, et al. Evaluating the impact of relative total dose intensity (RTDI) on patients' short and long‐term outcome in taxane‐ and anthracycline‐based chemotherapy of metastatic breast cancer–A pooled analysis. BMC Cancer. 2011;11:131. doi:10.1186/1471-2407-11-131
Lyman GH, Dale DC, Crawford J. Incidence and predictors of low dose‐intensity in adjuvant breast cancer chemotherapy: A nationwide study of community practices. J Clin Oncol. 2003;21(24):4524‐4531. doi:10.1200/jco.2003.05.002
Lyman GH, Dale DC, Friedberg J, Crawford J, Fisher RI. Incidence and predictors of low chemotherapy dose‐intensity in aggressive non‐Hodgkin's lymphoma: A nationwide study. J Clin Oncol. 2004;22(21):4302‐4311. doi:10.1200/jco.2004.03.213
Claessens AKM, Bos M, Lopez‐Yurda M, et al. Intermittent versus continuous first‐line treatment for HER2‐negative metastatic breast cancer: The Stop & Go study of the Dutch Breast Cancer Research Group (BOOG). Breast Cancer Res Treat. 2018;172(2):413‐423. doi:10.1007/s10549-018-4906-8
Hanna RK, Poniewierski MS, Laskey RA, et al. Predictors of reduced relative dose intensity and its relationship to mortality in women receiving multi‐agent chemotherapy for epithelial ovarian cancer. Gynecol Oncol. 2013;129(1):74‐80. doi:10.1016/j.ygyno.2012.12.017
Havrilesky LJ, Reiner M, Morrow PK, Watson H, Crawford J. A review of relative dose intensity and survival in patients with metastatic solid tumors. Crit Rev Oncol Hematol. 2015;93(3):203‐210. doi:10.1016/j.critrevonc.2014.10.006
Soff GA, Ray‐Coquard I, Rivera LJM, et al. Systematic literature review and meta‐analysis on use of thrombopoietic agents for chemotherapy‐induced thrombocytopenia. PLoS One. 2022;17(6):e0257673. doi:10.1371/journal.pone.0257673
Soff J, Bussel J. TPO‐mimetics for chemotherapy‐induced thrombocytopenia: timing matters. Leuk Lymphoma. 2018;59(12):2763‐2764. doi:10.1080/10428194.2018.1482545
Winer ES, Safran H, Karaszewska B, et al. Eltrombopag for thrombocytopenia in patients with advanced solid tumors receiving gemcitabine‐based chemotherapy: A randomized, placebo‐controlled phase 2 study. Int J Hematol. 2017;106(6):765‐776. doi:10.1007/s12185-017-2319-9
Winer ES, Safran H, Karaszewska B, et al. Eltrombopag with gemcitabine‐based chemotherapy in patients with advanced solid tumors: A randomized phase I study. Cancer Med. 2015;4(1):16‐26. doi:10.1002/cam4.326
Promacta® (eltromopag) Prescribing Information. Novartis Pharmaceuticals Corporation. 2024 https://us.promacta.com/sites/us_promacta_com/files/documents/promacta‐1.pdf
Nplate® (romiplostim). Prescribing Information. Amgen Inc; 2008 https://www.pi.amgen.com/‐/media/Project/Amgen/Repository/pi‐amgen‐com/Nplate/nplate_pi_hcp_english.pdf
Wang B, Nichol JL, Sullivan JT. Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand. Clin Pharmacol Ther. 2004;76(6):628‐638. doi:10.1016/j.clpt.2004.08.010
Natale R, Charu V, Schütte W, et al. 9248 safety of romiplostim for treatment of chemotherapy‐induced thrombocytopenia (CIT) in patients with advanced non‐small cell lung cancer (NSCLC). EJC Suppl. 2009;2(7):574.
Al‐Samkari H, Marshall AL, Goodarzi K, Kuter DJ. The use of romiplostim in treating chemotherapy‐induced thrombocytopenia in patients with solid tumors. Haematologica. 2018;103(4):e169‐e172. doi:10.3324/haematol.2017.180166
Parameswaran R, Lunning M, Mantha S, et al. Romiplostim for management of chemotherapy‐induced thrombocytopenia. Support Care Cancer. 2014;22(5):1217‐1222. doi:10.1007/s00520-013-2074-2
Le Rhun E, Devos P, Houillier C, et al. Romiplostim for temozolomide‐induced thrombocytopenia in glioblastoma: The PLATUM trial. Neurology. 2019;93(19):e1799‐e1806. doi:10.1212/wnl.0000000000008440
Wilkins CR, Ortiz J, Gilbert LJ, et al. Romiplostim for chemotherapy‐induced thrombocytopenia: efficacy and safety of extended use. Res Pract Thromb Haemost. 2022;6(3):e12701. doi:10.1002/rth2.12701
McElroy PL, Wei P, Buck K, et al. Romiplostim promotes platelet recovery in a mouse model of multicycle chemotherapy‐induced thrombocytopenia. Exp Hematol. 2015;43(6):479‐487. doi:10.1016/j.exphem.2015.02.004
Vadhan‐Raj S, Hagemeister F, Fayad LE, et al. Randomized, double‐blind, placebo‐controlled, dose and schedule‐finding study of AMG 531 in chemotherapy‐induced thrombocytopenia (CIT): results of a phase I/II study. Blood. 2010;116(21):1544. doi:10.1182/blood.V116.21.1544.1544
Song AB, Goodarzi K, Karp Leaf R, Kuter DJ, Al‐Samkari H. Thrombopoietin level predicts response to treatment with romiplostim in chemotherapy‐induced thrombocytopenia. Am J Hematol. 2021;96(12):1563‐1568. doi:10.1002/ajh.26338
Aapro M, Lyman GH, Bokemeyer C, et al. Supportive care in patients with cancer during the COVID‐19 pandemic. ESMO Open. 2021;6(1):100038. doi:10.1016/j.esmoop.2020.100038
Griffiths EA, Roy V, Alwan L, et al. NCCN guidelines® insights: Hematopoietic growth factors, version 1.2022. J Natl Compr Cancer Netw. 2022;20(5):436‐442. doi:10.6004/jnccn.2022.0026
Kuter DJ. The biology of thrombopoietin and thrombopoietin receptor agonists. Int J Hematol. 2013;98(1):10‐23. doi:10.1007/s12185-013-1382-0